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BACKGROUND: A recent genome-wide association study (GWAS) of autism spectrum disorder (ASD) (ncases =
18,381, ncontrols = 27,969) has provided novel opportunities for investigating the etiology of ASD. Here, we
integrate the ASD GWAS summary statistics with summary-level gene expression data to infer differential gene
expression in ASD, an approach called transcriptome-wide association study (TWAS).
METHODS: Using FUSION software, ASD GWAS summary statistics were integrated with predictors of gene
expression from 16 human datasets, including adult and fetal brains. A novel adaptation of established statistical
methods was then used to test for enrichment within candidate pathways and speciﬁc tissues and at different stages
of brain development. The proportion of ASD heritability explained by predicted expression of genes in the TWAS was
estimated using stratiﬁed linkage disequilibrium score regression.
RESULTS: This study identiﬁed 14 genes as signiﬁcantly differentially expressed in ASD, 13 of which were outside of
known genome-wide signiﬁcant loci (6500 kb). XRN2, a gene proximal to an ASD GWAS locus, was inferred to be
signiﬁcantly upregulated in ASD, providing insight into the functional consequence of this associated locus. One
novel transcriptome-wide signiﬁcant association from this study is the downregulation of PDIA6, which showed
minimal evidence of association in the GWAS, and in gene-based analysis using MAGMA. Predicted gene
expression in this study accounted for 13.0% of the total ASD single nucleotide polymorphism heritability.
CONCLUSIONS: This study has implicated several genes as signiﬁcantly up/downregulated in ASD, providing novel
and useful information for subsequent functional studies. This study also explores the utility of TWAS-based
enrichment analysis and compares TWAS results with a functionally agnostic approach.
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https://doi.org/10.1016/j.biopsych.2019.04.034Autism spectrum disorder (ASD) comprises a group of
neurodevelopmental disorders characterized by impaired
social and communication skills and stereotyped and repetitive
behaviors. ASD has a prevalence of 1% (1), with symptoms
typically starting in early childhood. Twin studies estimate the
heritability of ASD at between w65% and 90% (2,3), demon-
strating that genetic differences play an important role in the
development of ASD. Common genetic variation is an impor-
tant component of ASD liability, with a most recent single
nucleotide polymorphism (SNP) heritability estimate of 11.8%
on a liability scale (assuming prevalence of 1.2%) (4).
Genome-wide association studies (GWASs) are a powerful
approach for understanding the role of common alleles in the
genetic etiology of traits and disorders and have provided
several insights into the etiology of ASD. The most recent andª 2019 Society of B
N: 0006-3223 Biololargest ASD GWAS, including 18,381 ASD cases and 27,969
controls, reported three independent loci achieving genome-
wide signiﬁcance (4). Genes associated with ASD were high-
lighted through proximity to genome-wide signiﬁcant loci and
via joint statistical analysis of variants within gene regions.
However, a variant’s proximity to a gene is only one metric for
illuminating its functional consequence, and the nearest gene
often does not drive the association (5).
Another approach for highlighting genes that underlie
GWAS associations is integration of functional data. For
example, Grove et al. (4) used chromatin conformation data to
infer whether signiﬁcant ASD loci physically interact with the
surrounding genes. Alternatively, prior knowledge of variants
effecting gene expression, known as expression quantitative
trait loci, can be used to infer gene expression changesiological Psychiatry. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).
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fects. This is a powerful approach because the vast majority of
loci identiﬁed through GWASs of complex traits appear to be
mediated by altered gene regulation rather than changes in
protein coding sequence (6). Several methods exist for infer-
ring associated differential expression from GWAS summary
statistics, including Summary-data–based Mendelian
Randomization (SMR) (7) and transcriptome-wide association
study (TWAS) [as performed by FUSION (8) and MetaXcan (9)].
A key distinction between SMR and TWAS is that TWAS
considers the joint effect of multiple SNPs on a gene’s
expression and therefore has greater power than SMR when
there are multiple expression quantitative trait loci for a given
gene (9,10). In addition to prioritizing genes at genome-wide
signiﬁcant loci, TWAS is able to implicate genes in regions
containing no genome-wide signiﬁcant variants. For example,
a recent TWAS of schizophrenia identiﬁed 157 signiﬁcantly
associated genes, 35 of which were considered novel as they
were .500 kb from a genome-wide signiﬁcant locus (11).
Furthermore, by indicating how the regulation of the implicated
gene is affected by associated genetic variation, such studies
can more accurately inform functional follow-up investigations
and, potentially, therapeutic strategies.
In this study, we carried out a TWAS of ASD to identify gene
expression changes associated with these disorders. Using
the ASD TWAS results, and a novel adaptation of established
statistical methods, we also tested for enrichment within
candidate pathways, speciﬁc tissues, and stages of brain
development. Finally, we estimated the proportion of variance
in ASD that is attributable to these TWAS observations.
METHODS AND MATERIALS
Datasets
We performed a TWAS using the publicly available Psychiatric
Genomics Consortium 1 iPSYCH ASD GWAS summary sta-
tistics (4) (https://www.med.unc.edu/pgc/results-and-
downloads) and 16 sets of gene expression SNP weights
(Table 1). SNP weight sets captured gene expression for fetal
brain tissue and brain, blood, and adipose tissue in adults.
SNP weights for each gene-tissue pair is referred to as a
feature. Fetal brain features were derived using gene expres-
sion data collected from brain homogenates from 67 fetuses
12 to 19 weeks postconception, and genetically deﬁned to be
of European ancestry, collected through the Human Develop-
mental Biology Resource (12). Fetal brain features were
derived using the FUSION pipeline (http://gusevlab.org/
projects/fusion). CommonMind Consortium (CMC),
Netherlands Twin Registry (NTR), Young Finns Study (YFS),
Metabolic Syndrome in Men study (METSIM), and Genotype-
Tissue Expression project (GTEx) SNP weights were down-
loaded directly from the FUSION/TWAS website (http://
gusevlab.org/projects/fusion/). Analysis of genotypes and
gene expression from these datasets has been previously
described: CMC (11), NTR, YFS, METSIM (8), GTEx (13), and
fetal brain (12). See Supplement 1 for further details on deri-
vation of SNP weights. Less disease-relevant tissues, such as
adipose and blood, that were included as cis-expression
quantitative trait loci effects are moderately to highly corre-
lated across all tissues (14), and nonbrain datasets have266 Biological Psychiatry August 15, 2019; 86:265–273 www.sobp.orgrelatively large sample sizes, providing improved power to
detect signiﬁcantly cis-heritable gene expression.
Transcriptome-wide Association Study
Deﬁning Transcriptome-wide Signiﬁcance. We esti-
mated transcriptome-wide signiﬁcance as p = 4.25 3 1026
using a permutation procedure to account for the correlation
between features within and across SNP weight sets (see
Supplement 1). For comparison, false discovery rate (FDR)–
corrected p values were also calculated.
TWAS Analysis Using FUSION. TWAS analysis was per-
formed using the FUSION software with default settings (8).
Colocalization was performed to estimate the posterior
probability that GWAS and TWAS associations share a causal
SNP (see Supplement 1). Colocalization was performed using
the coloc R package, version 3.4.1 (R Foundation for Statistical
Computing, Vienna, Austria) (15), implemented by FUSION.
In regions containing multiple signiﬁcant associations, joint
analysis was performed to identify conditionally independent
associations. This was implemented using FUSION, with
genes considered in a joint model if the boundaries overlapped
60.5 Mb.
To pool evidence of association for each gene across SNP
weight sets, the multiple degrees-of-freedom omnibus test
was performed using FUSION.
Derivation of Non–TWAS-Informed Gene-Based
Statistics
TWAS has some similarities and differences to gene-based
MAGMA analysis (https://ctg.cncr.nl/software/magma) (see
Supplement 1). MAGMA’s gene-based analyses were per-
formed using the ASD GWAS summary statistics to enable a
direct comparison with the TWAS results. MAGMA analysis
was restricted to genes in the TWAS and contained at least
one SNP available in the ASD GWAS and 1000 Genomes
linkage disequilibrium (LD) reference. The SNP-wise mean
model was used in MAGMA to estimate gene associations, a
model also employed by other software (PLINK, VEGAS,
SKAT). SNPs were assigned to a gene if they were within 10 kb
of the gene.
TWAS-Based Enrichment Analysis
Analytical Procedure. TWAS-based enrichment analysis
was performed using a novel adaption of a previously estab-
lished method for GWAS-based enrichment analysis imple-
mented in the software MAGMA (16) (see Supplement 1). In
brief, enrichment analysis was performed using linear mixed
model regression of TWAS Z score on gene set membership,
accounting for the correlation between genes due to LD. We
analyzed TWAS association results from all 16 SNP weight
sets simultaneously to improve genome coverage and reduce
the multiple testing burden. The R package lme4qtl was used
to ﬁt the linear mixed model (17). The software used for this
analysis is publicly available (https://github.com/bulik/ldsc).
Gene Set Enrichment Analysis. TWAS results were
tested for enrichment across 173 candidate gene sets,
including 134 gene sets relevant to various aspects of/journal
Table 1. Descriptive Statistics for SNP Weight Sets in ASD TWAS
Study Tissue Typea Individualsb Featuresc ASD TWAS Signiﬁcant
O’Brien (12) Fetal brain Gene 67 831 2
O’Brien (12) Fetal brain Transcript 67 2865 (2295) 6 (5)
CMC Dorsolateral prefrontal cortex Gene 452 5379 1
CMC Dorsolateral prefrontal cortex Splicing 452 7735 (3297) 1
NTR Peripheral blood Gene 1247 2437 0
YFS Whole blood Gene 1264 4657 2
METSIM Adipose Gene 563 4637 0
GTEx Caudate basal ganglia Gene 100 944 0
GTEx Cerebellar hemisphere Gene 89 1512 1
GTEx Cerebellum Gene 103 2001 2
GTEx Cortex Gene 96 1047 0
GTEx Frontal cortex BA9 Gene 92 928 1
GTEx Hippocampus Gene 81 539 0
GTEx Hypothalamus Gene 81 602 2
GTEx Nucleus accumbens basal ganglia Gene 93 883 1
GTEx Putamen basal ganglia Gene 82 633 0
Total — — — 37,631 (13,243) 19 (14)
Numbers in parentheses for fetal brain transcript level and CMC dorsolateral prefrontal cortex indicate the number of unique genes.
ASD, autism spectrum disorder; BA, Brodmann area; CMC, CommonMind Consortium; GTEx, Genotype-Tissue Expression project; METSIM,
Metabolic Syndrome in Men study; NTR, Netherlands Twin Registry; SNP, single nucleotide polymorphism; TWAS, transcriptome-wide
association study; YFS, Young Finns Study.
aType indicates what the features for each dataset represent, i.e., gene-level expression, transcript-level expression, or splicing events.
bIndividuals in the reference sample used to derive the feature SNP weights.
cFeatures included in the TWAS for each SNP weight set.
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as central nervous system gene sets), 38 gene sets that have
been previously implicated in ASD speciﬁcally (herein
referred to as ASD-relevant gene sets), and a gene set
containing loss-of-function intolerant genes. The central
nervous system, loss-of-function (18,19), and ASD-related
gene sets (20) have been previously described. The FDR
method was used to correct for multiple testing across all
173 candidate gene sets.
The comparative analysis using non–TWAS-informed gene-
level associations was also performed using MAGMA.
Gene-Property Association Analysis. Gene-property
analysis estimates the relationship between TWAS associa-
tions and continuous gene annotations. Using BRAINSPAN
data (21), scores indicating preferential expression of each gene
at 19 developmental stages have been calculated (11). Using
the mixed model approach described above, the correlation
between preferential expression scores for each developmental
period and nonzero association gene Z scores was then
calculated. A signiﬁcance threshold of p , .05/19 was used.
For comparison, gene-property analysis was also per-
formed using the non–TWAS-informed gene-level associations
in MAGMA.
SNP Weight Set Enrichment Analysis. We also tested
for an enrichment of association across the SNP weight sets
used in this study to evaluate the importance of each tissue or
time point in ASD etiology. Secondary analysis was also per-
formed using only SNP weight sets for the basal ganglia to
compare each of the three basal ganglia components.Biological PsEstimating the Proportion of Heritability Mediated
by Gene Expression
The proportion of ASD heritability accounted for by the TWAS
results from each SNP weight set and all SNP weight sets com-
bined were estimated using stratiﬁed LD score regression (22)
(https://github.com/bulik/ldsc). FUSION was used to calculate
LD scores ﬁles that were restricted to SNPs within the TWAS
SNP weights, and LD scores were weighted to represent the
association between each SNP and predicted gene expression.
The total heritability of ASD was estimated using standard LD
score regression (23). The proportion of SNP-based heritability
accounted for by TWAS was calculated as the TWAS-based
heritability divided by the SNP-based heritability.RESULTS
ASD TWAS
Of the 16 SNP weight sets, 10 revealed transcriptome-wide
signiﬁcant associations, with the fetal brain transcript-level
weights returning the greatest number of signiﬁcant associa-
tions (5 unique genes) (Table 1). In total 19 transcriptome-wide
signiﬁcant associations were observed for 14 unique genes
(Figure S1 in Supplement 1). Following conditional analysis, 5
independent transcriptome-wide signiﬁcant associations were
observed (Table 2). Many of these associations achieved
transcriptome-wide signiﬁcance across multiple SNP weight
sets (Figure 1). Full TWAS association results are in Table S1 in
Supplement 2. Colocalization results are available in Table S2
in Supplement 2. When using an FDR-based transcriptome-
wide signiﬁcance threshold, 158 signiﬁcant features wereychiatry August 15, 2019; 86:265–273 www.sobp.org/journal 267
Table 2. List of Independent Transcriptome-wide Signiﬁcant Loci
Locationa MinP (TWAS)b MinP (GWAS)c MinP (MAGMA)d
Variance
Explained (%)e Jointly Signiﬁcantf Marginally Signiﬁcantg
chr2:10923518-10952970 1.8 3 1026 1.3 3 1024 4.3 3 1024 94.2 PDIA6 PDIA6
chr8:8998934-9002945 3.3 3 1027 1.8 3 1026 6.6 3 1027 76.5 RP11-10A14.3 RP11-10A14.3
chr8:11700033-11725646 2.0 3 1026 3.3 3 1026 1.1 3 1026 96.2 CTSB CTSB
chr17:44344403-44346060 5.0 3 1027 4.4 3 1026 1.6 3 1027 99.9 RP11-259G18.1 ARHGAP27, CRHR1-IT1,
DND1P1, KANSL1, KANSL1-
AS1, LRRC37A, LRRC37A4P,
MAPT, RN7SL739P, RP11-
259G18.1
chr20:21283941-21370463 1.8 3 1028 2.0 3 1029 1.9 3 1029 84.5 XRN2 XRN2
GWAS, genome-wide association study; SNP, single nucleotide polymorphism; TWAS, transcriptome-wide association study.
aChromosome and start/stop coordinates of the jointly signiﬁcant gene.
bMinimum p value across SNP weight sets for the jointly signiﬁcant gene.
cThe p value for top SNP association 6500 kb of the jointly signiﬁcant gene.
dThe p value of most signiﬁcant gene in MAGMA analysis 6500 kb of the jointly signiﬁcant gene.
eProportion of the MinP (GWAS) association explained by the most signiﬁcant TWAS feature in the region, calculated as 1 – (c2-conditioned
GWAS association/c2-unconditioned GWAS association).
fGenes that remain signiﬁcant after accounting for variance explained by all nearby marginally signiﬁcant genes.
gGenes that are no longer signiﬁcant after accounting for variance explained by surrounding jointly signiﬁcant genes; associations are considered
to be dependent if they are with 1 Mb of each other.
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Supplement 2).
Chromosome 20 p11.22. The strongest ASD TWAS as-
sociation was the upregulation of XRN2 based on YFS blood
SNP weights (p = 1.80 3 1028). Differential splicing of XRN2
also showed suggestive signiﬁcance based on the CMC pre-
frontal cortex SNP weights (p = 4.86 3 1026), and as a result
the omnibus test p value for XRN2 was 1.50 3 1028. Coloc-
alization supported model 4 with a posterior probability of
0.966, providing evidence that ASD liability and XRN2
expression associations are driven by the same causal variant.
XRN2 is within a locus previously associated with ASD at
genome-wide signiﬁcance in the ASD GWAS, with predicted
expression of XRN2 explaining 84.5% of the top SNP asso-
ciation (Table 2; Figure 2).
Chromosome 17 q21.31. A cluster of 14 transcriptome-
wide signiﬁcant associations (10 unique genes) were
observed within a 1-Mb region on chromosome 17 corre-
sponding to an inversion polymorphism that is common in
European populations (24). No single SNP within this region
achieved genome-wide signiﬁcance in the ASD GWAS. The
most signiﬁcant TWAS association in this region was the
upregulation of an RP11-259G18.1 transcript in the fetal brain,
explaining 99.9% of the ASD SNP association in this region
(Figure S2 in Supplement 1). Features in this region were highly
correlated (Figure S3 in Supplement 1) and therefore represent
a single association. Although RP11-259G18.1 showed the
strongest TWAS association, colocalization supported Model 4
(same causal variant as ASD) for all transcriptome-wide sig-
niﬁcant associations in this region.
Chromosome 8 p23.1. Two genes, CTSB (nucleus
accumbens basal ganglia) and RP11-10A14.3 (fetal brain
gene- and transcript-level), located 2.7 Mb apart on chromo-
some 8, achieved transcriptome-wide signiﬁcance. When268 Biological Psychiatry August 15, 2019; 86:265–273 www.sobp.orgconsidered in a joint model, both the transcript-level feature for
RP11-10A14.3 and gene-level feature for CTSB remained
nominally signiﬁcant, indicating that the signal driving the ASD
associations with RP11-10A14.3 and CTSB are broadly inde-
pendent. Although there are no genome-wide signiﬁcant SNPs
within 500 kb of these genes [previous deﬁnition of novel (11)],
they are either side of a genome-wide signiﬁcant locus
(rs4841432, chr8:10583506; p = 4.4 3 1028) (Figure S4 in
Supplement 1). In the joint model, the expression of CTSB and
RP11-10A14.3 together explains 60% of the association for
this genome-wide signiﬁcant SNP, demonstrating that these
TWAS associations are correlated with the previously identiﬁed
genome-wide signiﬁcant association and are therefore not
entirely novel. Colocalization provides weak evidence that
these association are driven by the same causal variant as
ASD, as the posterior probability is greater for model 4 (same
causal variant) than model 3 (different causal variant), but
individually weak SNP effects result in other models being the
preferred model (Table S2 in Supplement 2).
Chromosome 2 p25.1. The transcriptome-wide signiﬁcant
association between PDIA6 and ASD on chromosome 2 is in a
genomic region showing minimal evidence of association at
the SNP level, with the minimum p value being 1.3 3 1024 (62
Mb of PDIA6) (Figure S5 in Supplement 1). Colocalization
supports model 4, in which ASD and PDIA6 share a single
causal association.
Gene Set and Property Analysis
Full competitive gene set enrichment results are available in
Table S3 in Supplement 2. No gene sets were signiﬁcant after
FDR correction. Of the 135 central nervous system gene sets,
15 achieved nominal signiﬁcance, with the most signiﬁcant
being synaptic vesicle, presynapse, and abnormal axon guid-
ance (p , .015). Of the 38 ASD-related sets, one achieved
nominal signiﬁcance (Parikshak2013_M16). The M16 coex-
pression module represents early cortical development, with/journal
Figure 1. Transcriptome-wide signiﬁcant genes
across single nucleotide polymorphism (SNP) weight
sets. Transcriptome-wide signiﬁcance as a Z score is
w4.6. The direction of effect for splicing and tran-
script SNP weights should be interpreted with
caution owing to the often inverse relationship be-
tween alternative transcripts of the gene (11). Blank
squares indicate that the gene weights were not
available in the target tissue. BA, Brodmann area;
CMC, CommonMind Consortium; GTEx, Genotype-
Tissue Expression project; METSIM, Metabolic
Syndrome in Men study; NTR, Netherlands Twin
Registry; YFS, Young Finns Study.
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conception (25). The loss-of-function intolerant gene set
returned an enrichment p value of .194, which supports the
notion that mutation-intolerance metrics do not characterize
ASD GWAS loci, despite their association with ASD risk genes
identiﬁed through de novo variant studies (26).
Enrichment results of genes preferentially expressed during
one of 19 developmental periods in brain returned no signiﬁ-
cant associations (Figure S6 in Supplement 1). However,
preferential expression during 7 of the ﬁrst 8 developmental
stages (12 weeks postconception to 4 months) were positively
correlated with ASD TWAS association, and 7 of 11 later
stages (10 months to 40 years) were negatively correlated with
ASD TWAS association. This trend suggests that ASD TWAS
associations are stronger among genes showing high
expression during fetal development.
Enrichment analysis comparing the mean association of
features within each SNP weight set showed no signiﬁcant
enrichment (Figure 3), with fetal gene expression showing the
highest level of enrichment (p = .09). Secondary competitive
analysis of the 3 basal ganglia regions alone showed that geneBiological Psexpression in the putamen region was enriched at nominal
signiﬁcance in comparison with gene expression in the
caudate and nucleus accumbens (p = .03).Comparison of TWAS Results With MAGMA
MAGMA gene association analysis returned similar results to
those reported previously (4). Regions containing
transcriptome-wide signiﬁcant associations on chromosomes
8, 17, and 20 also contained signiﬁcant MAGMA-based as-
sociations (6500 kb of signiﬁcant TWAS feature), although
often implicated different genes within the same locus
(Tables S4 and S5 in Supplement 2; Figures S7–S12 in
Supplement 1). The only transcriptome-wide signiﬁcant locus
in which MAGMA identiﬁed no signiﬁcant associations was
that surrounding PDIA6 on chromosome 2. MAGMA identiﬁed
signiﬁcant associations in 2 loci that contained no signiﬁcant
associations in the TWAS. The signiﬁcant associations in these
2 loci were for NTM (11q25) and MACROD2 (20p12.1)
(Figures S9 and S11 in Supplement 1).Figure 2. Regional association plot. The top panel
shows all of the protein-coding genes or genes in the
transcriptome-wide association study. Jointly sig-
niﬁcant genes are highlighted in blue, nonsigniﬁcant
(NS) genes are highlighted in red, and genes that
were not in the transcriptome-wide association study
(NA) are in gray. The bottom panel shows a Man-
hattan plot of the genome-wide association study
data before (gray) and after (blue) conditioning on the
jointly signiﬁcant genes.
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Figure 3. The left panel shows the autism spec-
trum disorder (ASD) single nucleotide polymorphism
(SNP) heritability explained by predicted gene
expression on a liability scale. The right panel shows
results of competitive gene set enrichment analysis
for SNP weight sets (i.e., whether features within
each SNP weight set are on average more associ-
ated with ASD than compared with features in all
other SNP weight sets). BA, Brodmann area; CMC,
CommonMind Consortium; GTEx, Genotype-Tissue
Expression project; METSIM, Metabolic Syndrome
in Men study; NTR, Netherlands Twin Registry;
TWAS, transcriptome-wide association study; YFS,
Young Finns Study.
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MAGMA-based gene set analysis using ASD GWAS summary
statistics of candidate gene sets returned no signiﬁcant as-
sociations after FDR correction (Table S3 in Supplement 2).
The rank-based correlation between MAGMA- and TWAS-
based gene set association results was 0.23.
Gene property analysis for enrichment of genes preferentially
expressed during a given period of brain development showed
a similar pattern of results as the TWAS-based gene property
analysis, with a rank-based correlation of 0.39. Although no
developmental stage achieved signiﬁcance in the MAGMA
analysis after Bonferroni correction, preferential expression in 3
fetal stages of brain development were positively associated at
nominal signiﬁcance, and preferential expression in 1 adult
brain stage (.19 years) was negatively associated at nominal
signiﬁcance (Figure S6 in Supplement 1).
Proportion of Heritability
LD score regression estimated the total ASD SNP heritability
at .120 (SE = .010; p = 4.72 3 10232) on a liability scale
assuming a population prevalence of 1.2%. When considering
TWAS results from all SNP weight sets together, the heritability
was .0155 on a liability scale, and the proportion of ASD SNP
heritability explained was 13%. The TWAS-based heritability
estimates were all signiﬁcantly nonzero (Figure 3; Table S6 in
Supplement 2). TWAS-based heritability estimates should not
be interpreted as a measure of enrichment (see Supplement 1).
DISCUSSION
This is study has inferred differential gene expression/splicing
associated with ASD across a range of tissues using the TWAS
method and has provided several novel insights into the
etiology of ASD.
This study demonstrates that the previously reported
genome-wide signiﬁcant locus spanning multiple genes within270 Biological Psychiatry August 15, 2019; 86:265–273 www.sobp.orgthe locus at 20 to 21 Mb of chromosome 20 is linked to
signiﬁcant differential expression and splicing of the gene
XRN2. Functionally agnostic gene-based analysis in MAGMA
also identiﬁes XRN2 as signiﬁcant, as reported in this study
and previously by Grove et al. (4). Moreover, a recent study
reported evidence that ASD associated SNPs in this region
colocalize with several DNA methylation sites (27), although
the consequence of this methylation on surrounding gene
expression is unknown. Our data point to differential
expression of XRN2 in the blood and differential splicing in
the prefrontal cortex. XRN2 is an essential nuclear 50/30
exoRNase with a multitude of functions in the processing and
regulation of RNA molecules. XRN2 has been identiﬁed as an
essential gene for the survival of multiple human cell lines
(28–30), and individuals diagnosed with ASD have been
shown to have an increased number of deleterious mutations
among essential genes (31), again supporting a role for XRN2
in ASD etiology.
This study also highlighted 13 transcriptome-wide signiﬁ-
cant genes outside loci achieving genome-wide signiﬁcance
in the corresponding ASD GWAS (6500 kb), 10 of which
surround the 17q21 inversion. Five of the 10 signiﬁcant genes
surrounding the 17q21 inversion are also identiﬁed as signif-
icantly associated using the functionally agnostic region-
based approach employed by MAGMA, of which several
were previously reported by Grove et al. (4). The inversion at
17q21, which has a population frequency of around 20% in
Europeans, has been previously highlighted as an ASD
susceptibility locus through linkage analysis (32) and family-
based GWAS (33). The 900-kb inverted region, which con-
tains many known genes, is marked by extensive LD,
complicating identiﬁcation of the causal susceptibility genes.
One study used a ﬁne-mapping approach and implicated
CACNA1G as a ASD susceptibility gene in the region (34).
Results from our TWAS show no evidence of association
between ASD and CACNA1G expression (p = .33 based on/journal
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ping to this region have recently been implicated in the per-
sonality trait of neuroticism (12) [genes listed in Tables S8 and
S9 of O’Brien et al. (12)].
The only locus containing a transcriptome-wide signiﬁcant
gene that is not signiﬁcantly implicated by either GWAS or
MAGMA was PDIA6 on chromosome 2. This discovery high-
lights the advantage of TWAS, which incorporates additional
functional information of genetic variants as opposed to relying
purely on the proximity of SNPs to a gene.
Previous studies using the TWAS approach commonly
report associations as novel if the associated feature is outside
of genome-wide signiﬁcant loci in the corresponding GWAS
(11,35). However, given that TWAS is a gene-based approach,
it gains power not only from incorporating functional annota-
tions, but also by pooling evidence across multiple genetic
variants. Therefore, we have compared the TWAS results to
those from the functionally agnostic gene-based approach
employed in MAGMA (and other software) to more clearly
distinguish the novel insights that TWAS can provide. This
comparison demonstrated that 4 of the 5 regions containing
independent ASD TWAS associations also contained signiﬁ-
cant associations identiﬁed by the functionally agnostic
approach, suggesting that pooling information across genetic
variants often highlights regions of novel association. How-
ever, the genes implicated often differed between the two
gene-based approaches. A key advantage of TWAS is that it
considers the functional annotations of associated genetic
variants and can therefore provide mechanistic insight into
how a regional association is mediated. This is valuable in-
formation for subsequent experimental studies aiming to un-
derstand the mechanism underlying the genetic association
and could be used to improve subsequent gene-level statisti-
cal analyses. However, TWAS only assesses genes showing
statistically signiﬁcant cis-heritable expression and is therefore
dependent on the sample size of the gene expression refer-
ence. As functionally agnostic region-based approaches do
not suffer from this limitation, we consider the two approaches
to be complimentary, with TWAS as a useful downstream
approach for reﬁning and assigning directionality to gene
associations.
The two transcriptome-wide signiﬁcant associations on
chromosome 8, CTSB and RP11-10A14.3, were proximal to a
genome-wide signiﬁcant locus in the corresponding GWAS.
MAGMA analysis identiﬁed 6 genes within this region
achieving signiﬁcance (Tables S4 and S5 in Supplement 2);
however, no gene was identiﬁed as signiﬁcant by both TWAS
and MAGMA. Additional support for this locus comes from
repeated studies showing duplications in this region (8p23.1-3)
in individuals with ASD (36–38). However, the gene/genes
driving this association have not been identiﬁed. This TWAS
found evidence that CTSB is upregulated in ASD across mul-
tiple brain tissues. CTSB encodes cathepsin B, a cysteine
protease reported to mediate exercise enhanced hippocampal
neurogenesis and spatial memory (39), and inhibitors of
cathepsin B have therapeutic potential for traumatic brain
injury (40). Furthermore, treating rodent neuroprogenitor cells
with exogenous cathepsin B is associated with differential
expression of multiple neurogenesis-related genes (39). These
previous ﬁndings suggest that differential expression of CTSBBiological Psleads to differences in neurogenesis and neuronal cell death,
and therefore is a plausible candidate for ASD. Cathepsin B is
also an amyloid precursor protein secretase, and inhibition of it
has been reported as a potential therapeutic for Alzheimer’s
disease (41). This is interesting, given prior evidence of shared
etiology between ASD and Alzheimer’s disease (42,43). RP11-
10A14.3 is an antisense RNA with an unknown function.
Several other genes in this region show suggestive evidence of
differential expression/splicing in ASD (Figure S8 in
Supplement 1), including MSRA, which has been previously
associated with schizophrenia (44), MFHAS1, and PINX1.
Finally, of the TWAS implicated genes, downregulation of
PDIA6 in the blood was signiﬁcantly associated with ASD.
PDIA6 encodes a member of the protein disulﬁde isomerase
family, which play an important role in protein folding. Owing to
their role in protein folding, they have been implicated in
several neurodegenerative diseases (45); however, there is little
evidence of a connection between protein disulﬁde isomerases
and neurodevelopmental phenotypes. Further research into
the potential role of protein disulﬁde isomerase proteins in ASD
is needed. PDIA6 expression could be assessed only in blood
owing to limited power in other tissues and must be replicated
in disease-relevant tissues as and when they become
available.
Predicted gene expression based on all SNP weights sets
separately and together explained a signiﬁcant amount of
variance in ASD liability, collectively accounting for 13% of the
ASD SNP heritability. This indicates that gene expression is
important in the etiology of ASD.
One other study has applied the TWAS approach to the
ASD GWAS summary statistics used in this study (46). Gandal
et al. (46) infer differential expression in ASD using data from
postnatal frontal and temporal cerebral cortex tissue within the
PsychENCODE consortium (N = 1695), which includes the
CMC data used in our study. Gandal et al. (46) report 3 loci
containing signiﬁcant associations, all of which overlap with
loci highlighted in this study (8p23, 17q21, 20p11). Our results
based on nonoverlapping expression data support several of
the associations found by Gandal et al. (46) and vice versa
(Tables S7 and S8 in Supplement 2). One association Gandal
et al. (46) prioritized is the upregulation of LRRC37A, which our
study found to be signiﬁcantly upregulated in fetal brain tissue.
A role for LRRC37A in ASD during fetal development is further
supported by Hi-C (chromatin) interaction analysis from inde-
pendent fetal brain data (4).
Gandal et al. (46) also performed the largest analysis of
differential expression in ASD based on postmortem brain
tissue. Several of the signiﬁcant ASD TWAS associations
identiﬁed in our study also show evidence of differential
expression in ASD based on observed gene- and transcript-
speciﬁc expression from postmortem brain tissue (Tables S9
and S10 in Supplement 2). Signiﬁcant TWAS associations
that are nominally signiﬁcant based on observed postmortem
data include PDIA6, CTSB, LRRC37A4P, CRHR1-IT1, MAPT,
KANSL1, and LRRC37A.
There are three key limitations to this study. First, TWAS
identiﬁes genetic variation that is associated with two out-
comes (here, ASD and gene expression/splicing), with subse-
quent colocalization analysis to determine whether the
association is driven by linkage (2 causal SNPs in LD with eachychiatry August 15, 2019; 86:265–273 www.sobp.org/journal 271
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50 Yearsother) or pleiotropy (same causal SNP). However, neither
TWAS nor colocalization can determine whether the associa-
tion is causal (the expression mediates the association be-
tween SNP and phenotype). Additional studies are required to
validate the causal relationship between gene expression
changes and ASD. Second, the SNP weights used for pre-
dicting differential expression/splicing are based on relatively
small sample sizes and therefore cannot infer all features that
are cis-regulated across all tissues. As a consequence, there
may be features that are important for the etiology of ASD that
we are unable to capture currently using TWAS. Finally, the
sample size of the ASD GWAS is still relatively small, and
therefore power to detect associations is also relatively low.
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